中山大学肿瘤防治中心，又名中山大学附属肿瘤医院和中山大学肿瘤研究所，原名华南肿瘤医院，是位于中华人民共和国广东省广州市的三级甲等医院，于1964年3月1号开始创办，现为中国内地规模最大、学术力量最雄厚的集医疗、教学、科研、预防于一体的肿瘤学医、教、研基地。

During the past decade, Sun Yet-sen University Cancer Center conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 7 clinical trials were completed, i.e. on average, 21.2% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 5 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sun Yet-sen University Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 26 trials, followed by "Sun Yat-sen University" with 3 trials sponsored, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 2 trials sponsored, "Merck Sharp & Dohme LLC" with 2 trials sponsored and "Genentech, Inc." with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sun Yet-sen University Cancer Center" #1 collaborator was "Breast International Group" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "GOG Foundation" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Guangdong Xiangxue Precision Medical Technology Co., Ltd." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Sun Yet-sen University Cancer Center" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Breast Cancer" (2 trials), "Carcinoma, Hepatocellular" (2 trials), "Colorectal Cancer" (2 trials) and "Diffuse Large B-Cell Lymphoma" (2 trials). Many other conditions were trialed in "Sun Yet-sen University Cancer Center" in a lesser frequency.

Most popular intervention types in "Sun Yet-sen University Cancer Center" are "Drug" (34 trials), "Biological" (3 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (12 trials), "Bevacizumab" (4 trials), "Cyclophosphamide" (4 trials), "Docetaxel" (4 trials) and "Doxorubicin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Sun Yet-sen University Cancer Center" are 34 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Sun Yet-sen University Cancer Center". 2 are not yet recruiting, 15 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Sun Yet-sen University Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sun Yet-sen University Cancer Center, 5 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".